Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Update

Inovio Pharmaceuticals, Inc. (NASDAQ:INOGet Rating) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 34,410,000 shares, a drop of 20.5% from the May 15th total of 43,310,000 shares. Based on an average daily volume of 5,830,000 shares, the short-interest ratio is presently 5.9 days.

A number of analysts recently weighed in on INO shares. StockNews.com upgraded shares of Inovio Pharmaceuticals to a “sell” rating in a report on Monday, May 23rd. Cantor Fitzgerald decreased their target price on shares of Inovio Pharmaceuticals from $6.00 to $3.00 in a research note on Wednesday, May 11th. Oppenheimer lowered shares of Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 11th. Finally, Royal Bank of Canada decreased their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 2nd. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.80.

Shares of Inovio Pharmaceuticals stock traded down $0.02 during trading on Thursday, hitting $1.51. 191,626 shares of the company’s stock traded hands, compared to its average volume of 5,344,951. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.74 and a quick ratio of 6.74. The firm’s fifty day moving average price is $2.35 and its 200 day moving average price is $3.68. Inovio Pharmaceuticals has a twelve month low of $1.40 and a twelve month high of $9.96. The company has a market cap of $344.71 million, a PE ratio of -0.97 and a beta of 0.82.

Inovio Pharmaceuticals (NASDAQ:INOGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). Inovio Pharmaceuticals had a negative net margin of 20,479.29% and a negative return on equity of 76.48%. The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.66 million. During the same quarter last year, the firm earned ($0.27) earnings per share. Inovio Pharmaceuticals’s quarterly revenue was down 46.4% on a year-over-year basis. As a group, equities research analysts anticipate that Inovio Pharmaceuticals will post -1.19 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. ProShare Advisors LLC increased its stake in Inovio Pharmaceuticals by 4.7% in the fourth quarter. ProShare Advisors LLC now owns 74,797 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 3,362 shares in the last quarter. WINTON GROUP Ltd increased its stake in Inovio Pharmaceuticals by 12.5% in the fourth quarter. WINTON GROUP Ltd now owns 31,567 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 3,519 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Inovio Pharmaceuticals by 16.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 27,793 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 3,936 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Inovio Pharmaceuticals by 3.4% in the fourth quarter. Parametric Portfolio Associates LLC now owns 136,064 shares of the biopharmaceutical company’s stock valued at $679,000 after purchasing an additional 4,519 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Inovio Pharmaceuticals by 12.3% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 44,845 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 4,897 shares in the last quarter. 43.28% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Recommended Stories

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.